Top

Published in:

Open Access 01-12-2015 | Original research

Radiation dosimetry and biodistribution in non-human primates of the sodium/iodide PET ligand [¹⁸F]-tetrafluoroborate

Authors: J. M. Marti-Climent, M. Collantes, M. Jauregui-Osoro, G. Quincoces, E. Prieto, I. Bilbao, M. Ecay, J. A. Richter, I. Peñuelas

Published in: EJNMMI Research | Issue 1/2015

Abstract

Background

[¹⁸F]-tetrafluoroborate is a PET radiotracer taken up by the sodium/iodide symporter (NIS). Albeit the in vivo behavior in rodents is similar to the ^99mTc-pertechnetate, no studies exist in primates or in humans. The aims of this study were to evaluate the biodistribution of [¹⁸F]-tetrafluoroborate in non-human primates with PET and to estimate the absorbed dose in organs.

Methods

Whole-body PET imaging was done in a Siemens ECAT HR+ scanner in two male Macaca fascicularis monkeys. After an i.v. injection of 24.93 ± 0.05 MBq/kg of [¹⁸F]-tetrafluoroborate, prepared by isotopic exchange of sodium tetrafluoroborate with [¹⁸F]-fluoride under acidic conditions, eight sequential images from the head to the thigh (five beds) were collected for a total duration of 132 min. The whole-body emission scan was reconstructed applying attenuation and scatter corrections. After image reconstruction, three-dimensional volumes of interest (VOIs) were hand-drawn on the PET transaxial or coronal slices of the frame where the organ was most conspicuous. Time-activity curves for each VOI were obtained, and the organ residence times were calculated by integration of the time-activity curves. Human absorbed doses were estimated using the OLINDA/EXM software and the standard human model.

Results

[¹⁸F]-tetrafluoroborate was able to discriminate clearly the thyroid gland with an excellent signal-to-noise ratio. Most of the radiotracers (residence time) are localised in the organs that express NIS (stomach wall, salivary glands, thyroid, olfactory mucosa), are involved in excretion (kidneys and bladder), or reflect the vascular phase (heart and lungs). Considering the OLINDA source organs, the critical organs were the stomach wall, thyroid and bladder wall, with absorbed doses lower than 0.078 mGy/MBq. The effective dose was 0.025 mSv/MBq.

Conclusions

[¹⁸F]-tetrafluoroborate is a very useful radiotracer for PET thyroid imaging in primates, with a characteristic biodistribution in organs expressing NIS. It delivers an effective dose slightly higher than the dose produced by ^99mTc-pertechnetate but much lower than that produced by radioiodine in the form of ¹³¹INa, ¹²³INa, or ¹²⁴INa.

Available only for authorised users

Bruno R, Giannasio P, Ronga G, Baudin E, Travagli JP, Russo D, et al. Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues. J Endocrinol Invest. 2004;27:1010–4.CrossRefPubMed

Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, et al. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev. 2003;24:48–77.CrossRefPubMed

Vayre L, Sabourin JC, Caillou B, Ducreux M, Schlumberger M, Bidart JM. Immunohistochemical analysis of Na symporter distribution in human extra-thyroidal tissues. Eur J Endocrinol. 1999;141:382–6.CrossRefPubMed

Micali S, Bulotta S, Puppin C, Territo A, Navarra M, Bianchi G, et al. Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer. BMC Cancer. 2014;14:303,2407-14-303.CrossRef

Ahn BC. Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back. Theranostics. 2012;2:392–402.PubMedCentralCrossRefPubMed

Penheiter AR, Russell SJ, Carlson SK. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Curr Gene Ther. 2012;12:33–47.PubMedCentralCrossRefPubMed

Eschmann SM, Reischl G, Bilger K, Kupferschlager J, Thelen MH, Dohmen BM, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging. 2002;29:760–7.CrossRefPubMed

Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45:1366–72.PubMed

Jauregui Osoro M, Sunassee K, Weeks A, Berry D, Paul R, Cleij M, et al. Synthesis and biological evaluation of [(18)F]tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter. Eur J Nucl Med Mol Imaging. 2010;37:2108–16.PubMedCentralCrossRefPubMed

10.

Eskandari S, Loo DD, Dai G, Levy O, Wright EM, Carrasco N. Thyroid Na+/I- symporter. Mechanism, stoichiometry, and specificity. J Biol Chem. 1997;272:27230–8.CrossRefPubMed

11.

ANBAR M, GUTTMANN S, LEWITUS Z. The accumulation of fluoroborate ions in thyroid glands of rats. Endocrinology. 1960;66:888–90.CrossRefPubMed

12.

Youn H, Jeong JM, Chung JK. A new PET probe, (18)F-tetrafluoroborate, for the sodium/iodide symporter: possible impacts on nuclear medicine. Eur J Nucl Med Mol Imaging. 2010;37:2105–7.CrossRefPubMed

13.

Weeks A, Jauregui Osoro M, Cleij M, Blower J, Ballinger J, Blower P. Evaluation of [18 F]-tetrafluoroborate as a potential PET imaging agent for the human sodium/iodide symporter in a new colon carcinoma cell line, HCT116, expressing hNIS. Nucl Med Commun. 2011;32:98–105.CrossRefPubMed

14.

Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med. 1997;38:1614–23.PubMed

15.

Brown AK, Fujita M, Fujimura Y, Liow JS, Stabin M, Ryu YH, et al. Radiation dosimetry and biodistribution in monkey and man of 11C-PBR28: a PET radioligand to image inflammation. J Nucl Med. 2007;48:2072–9.CrossRefPubMed

16.

Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.PubMed

17.

Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med. 2001;42:213–21.PubMed

18.

Antenor-Dorsey JA, Laforest R, Moerlein SM, Videen TO, Perlmutter JS. Radiation dosimetry of N-([11C]methyl)benperidol as determined by whole-body PET imaging of primates. Eur J Nucl Med Mol Imaging. 2008;35:771–8.PubMedCentralCrossRefPubMed

19.

Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, et al. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med. 2004;45:1725–33.PubMed

20.

Senthamizhchelvan S, Hobbs RF, Song H, Frey EC, Zhang Z, Armour E, et al. Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma. J Nucl Med. 2012;53:215–24.PubMedCentralCrossRefPubMed

21.

Jentzen W, Hobbs RF, Stahl A, Knust J, Sgouros G, Bockisch A. Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37:884–95.PubMedCentralCrossRefPubMed

22.

Doss M, Kolb HC, Zhang JJ, Belanger MJ, Stubbs JB, Stabin MG, et al. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans. J Nucl Med. 2012;53:787–95.CrossRefPubMed

23.

Doss M, Zhang JJ, Belanger MJ, Stubbs JB, Hostetler ED, Alpaugh K, et al. Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and humans determined by using whole-body PET/CT. Nucl Med Commun. 2010;31:1016–24.PubMedCentralPubMed

24.

Schaafsma IA, Pollak YW, Barthez PY. Effect of four sedative and anesthetic protocols on quantitative thyroid scintigraphy in euthyroid cats. Am J Vet Res. 2006;67:1362–6.CrossRefPubMed

25.

Spitzweg C, Joba W, Eisenmenger W, Heufelder AE. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab. 1998;83:1746–51.CrossRefPubMed

26.

Vidal JD, Mirabile RC, Thomas HC. Evaluation of the cynomolgus monkey stomach: recommendations for standard sampling procedures in nonclinical safety studies. Toxicol Pathol. 2008;36:250–5.CrossRefPubMed

27.

Russo D, Scipioni A, Durante C, Ferretti E, Gandini L, Maggisano V, et al. Expression and localization of the sodium/iodide symporter (NIS) in testicular cells. Endocrine. 2011;40:35–40.CrossRefPubMed

28.

International Commission on Radiological Protection (ICRP). Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). Ann ICRP. 1998;28:1–126.

29.

International Commission on Radiological Protection (ICRP). Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann ICRP 1988;18:1–4.

Title: Radiation dosimetry and biodistribution in non-human primates of the sodium/iodide PET ligand [18F]-tetrafluoroborate
Authors: J. M. Marti-Climent
M. Collantes
M. Jauregui-Osoro
G. Quincoces
E. Prieto
I. Bilbao
M. Ecay
J. A. Richter
I. Peñuelas
Publication date: 01-12-2015
Publisher: Springer Berlin Heidelberg
Published in: EJNMMI Research / Issue 1/2015
Electronic ISSN: 2191-219X
DOI: https://doi.org/10.1186/s13550-015-0148-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Radiation dosimetry and biodistribution in non-human primates of the sodium/iodide PET ligand [¹⁸F]-tetrafluoroborate

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Correlation between apoptosis and left ventricular remodeling in subacute phase of myocardial ischemia and reperfusion

The effect of radiation exposure on multidrug resistance: in vitro and in vivo studies using non-small lung cancer cells

Imaging of reactive oxygen species using [3H]hydromethidine in mice with cisplatin-induced nephrotoxicity

Differentiation of malignant tumours from granulomas by using dynamic [18F]-fluoro-L-α-methyltyrosine positron emission tomography

Effect of postconditioning on dynamic expression of tenascin-C and left ventricular remodeling after myocardial ischemia and reperfusion

A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice